000282968 001__ 282968
000282968 005__ 20251219151551.0
000282968 0247_ $$2doi$$a10.1038/s41531-025-01232-4
000282968 0247_ $$2pmid$$apmid:41361244
000282968 0247_ $$2pmc$$apmc:PMC12689644
000282968 037__ $$aDZNE-2025-01420
000282968 041__ $$aEnglish
000282968 082__ $$a610
000282968 1001_ $$aHähnel, Tom$$b0
000282968 245__ $$aBrain age gap as predictor of disease progression in Parkinson's disease.
000282968 260__ $$a[London]$$bSpringer Nature$$c2025
000282968 3367_ $$2DRIVER$$aarticle
000282968 3367_ $$2DataCite$$aOutput Types/Journal article
000282968 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1766153431_31933
000282968 3367_ $$2BibTeX$$aARTICLE
000282968 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282968 3367_ $$00$$2EndNote$$aJournal Article
000282968 520__ $$aParkinson's disease (PD) exhibits high heterogeneity in disease progression, complicating management and increasing required sample sizes for clinical trials. This study evaluates Brain Age Gap (BAG)-the difference between brain age and chronological age-for predicting disease progression in PD. Structural MRI-derived gray matter volumes were analyzed for 451 early-stage PD patients and 172 healthy controls from the PPMI cohort. PD patients had a baseline BAG of 1.1 years, with fast-progressing patients exhibiting a BAG of 3.0 years, whereas slow-progressing patients resembled the BAG of healthy controls. Higher BAG was associated with more severe baseline symptoms, faster cognitive decline in several domains, increased hazard of developing mild cognitive impairment, and faster progression of dopaminergic neuron loss in longitudinal DaTSCANs. BAG-based patient stratification could reduce sample sizes of randomized clinical trials by 23-58%. These findings suggest BAG as a prognostic biomarker of disease progression, which may accelerate the development of disease-modifying treatments.
000282968 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000282968 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000282968 7001_ $$aMore, Shammi$$b1
000282968 7001_ $$aHoffstaedter, Felix$$b2
000282968 7001_ $$aPatil, Kaustubh R$$b3
000282968 7001_ $$aFröhlich, Holger$$b4
000282968 7001_ $$0P:(DE-2719)2814178$$aFalkenburger, Björn H$$b5$$eLast author$$udzne
000282968 773__ $$0PERI:(DE-600)2819218-7$$a10.1038/s41531-025-01232-4$$gVol. 11, no. 1, p. 353$$n1$$p353$$tnpj Parkinson's Disease$$v11$$x2373-8057$$y2025
000282968 8564_ $$uhttps://pub.dzne.de/record/282968/files/DZNE-2025-1420.pdf$$yRestricted
000282968 8564_ $$uhttps://pub.dzne.de/record/282968/files/DZNE-2025-1420.pdf?subformat=pdfa$$xpdfa$$yRestricted
000282968 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2814178$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000282968 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000282968 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNPJ PARKINSONS DIS : 2022$$d2024-12-11
000282968 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-11
000282968 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-11
000282968 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-04-10T15:43:48Z
000282968 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-04-10T15:43:48Z
000282968 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-04-10T15:43:48Z
000282968 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2024-04-10T15:43:48Z
000282968 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-11
000282968 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-11
000282968 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-11
000282968 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-11
000282968 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-11
000282968 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNPJ PARKINSONS DIS : 2022$$d2024-12-11
000282968 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-11
000282968 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-11
000282968 9201_ $$0I:(DE-2719)1710012$$kAG Falkenburger$$lTranslational Parkinson Research$$x0
000282968 980__ $$ajournal
000282968 980__ $$aEDITORS
000282968 980__ $$aVDBINPRINT
000282968 980__ $$aI:(DE-2719)1710012
000282968 980__ $$aUNRESTRICTED